Across TCGA pan-cancer cohorts, MTCYBP2 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated MTCYBP2 data layer.
The strongest signal is observed in mesothelioma (MESO), where higher MTCYBP2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTCYBP2 expression acts as an unfavorable survival marker, although some lineages such as LAML and GBM show a favorable association.
MESO, PAAD, and KIRP are the cancer types where MTCYBP2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.